Literature DB >> 16353156

Development of multidrug resistance due to multiple factors including P-glycoprotein overexpression under K-selection after MYC and HRAS oncogene activation.

Yukari Nakamura1, Hiroyuki Sato, Toru Motokura.   

Abstract

Multistep tumorigenesis is a form of microevolution consisting of mutation and selection. To clarify the role of selection modalities in tumor development, we examined two alternative evolutionary conditions, r-selection in sparse culture, which allows cells to proliferate rapidly, and K-selection in confluent culture, in which overcrowding constrains cell proliferation. Using MYC- and EJ-RAS-transformed rat embryo fibroblasts, we found that K-selected cells acquired and stably maintained multidrug resistance (MDR) to DOX, VCR, MTX and Ara-C. Then, we examined the involvement of a number of factors potentially causal of the development of MDR, that is, ploidy, Tp53 mutation, doubling time and the expression levels of genes related to drug resistance. Although ploidy status and Tp53 mutations did not correlate with MDR, we found that Abcb1/Mdr1, encoding P-glycoprotein (Pgp), was significantly upregulated after K-selection. Cyclosporin A, a competitive inhibitor of Pgp, increased the intracellular accumulation of DOX and reduced the resistance to it. Indeed, the population of Pgp-transfected cells significantly expanded under K-, but not under r-selection. In addition to Pgp upregulation, altered expression of other genes such as Cda/cytidine deaminase and Slc29a1/equilibrative nucleoside transporter 1 and prolonged doubling times were associated with MDR. This system reproduces events associated with MDR in vivo and would be useful for analysis of MDR development. Copyright (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16353156     DOI: 10.1002/ijc.21691

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

Review 1.  Starvation, detoxification, and multidrug resistance in cancer therapy.

Authors:  Changhan Lee; Lizzia Raffaghello; Valter D Longo
Journal:  Drug Resist Updat       Date:  2012-03-04       Impact factor: 18.500

2.  Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer.

Authors:  Yunching Chen; Surendar Reddy Bathula; Jun Li; Leaf Huang
Journal:  J Biol Chem       Date:  2010-05-11       Impact factor: 5.157

3.  TRAIL sensitize MDR cells to MDR-related drugs by down-regulation of P-glycoprotein through inhibition of DNA-PKcs/Akt/GSK-3beta pathway and activation of caspases.

Authors:  Suk-Bin Seo; Jung-Gu Hur; Mi-Ju Kim; Jae-Won Lee; Hak-Bong Kim; Jae-Ho Bae; Dong-Wan Kim; Chi-Dug Kang; Sun-Hee Kim
Journal:  Mol Cancer       Date:  2010-07-28       Impact factor: 27.401

4.  Influence of multidrug resistance on (18)F-FCH cellular uptake in a glioblastoma model.

Authors:  Claire Vanpouille; Nathalie Le Jeune; David Kryza; Anthony Clotagatide; Marc Janier; Francis Dubois; Nathalie Perek
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-20       Impact factor: 9.236

5.  Aberrant overexpression of an epithelial marker, 14-3-3sigma, in a subset of hematological malignancies.

Authors:  Toru Motokura; Yukari Nakamura; Hiroyuki Sato
Journal:  BMC Cancer       Date:  2007-11-25       Impact factor: 4.430

6.  Galectin-3 silencing inhibits epirubicin-induced ATP binding cassette transporters and activates the mitochondrial apoptosis pathway via β-catenin/GSK-3β modulation in colorectal carcinoma.

Authors:  Yung-Kuo Lee; Tsung-Hsien Lin; Chuan-Fa Chang; Yu-Li Lo
Journal:  PLoS One       Date:  2013-11-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.